About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Nashville | 15,379 Studies Near You | Clareo Health

Clinical Trials LocationsNashville

Clinical Trials in Nashville

Discover 15,379 clinical trials near Nashville, Tennessee. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 3181-3200 of 15,379 trials

COMPLETEDPhase 1/2< 1 mile

Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus

NCT02052739

The purpose of this study is to evaluate the safety and tolerability of SAGE-547 in participants in super-refractory status epilepticus (SRSE).

Super-refractory Status Epilepticus

Supernus Pharmaceuticals, Inc.25 participantsStarted Mar 2014

Birmingham, Alabama, United States • Sarasota, Florida, United States • Chicago, Illinois, United States +14 more locations

COMPLETEDPhase 2< 1 mile

A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)

NCT05107128

The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance and functioning in participants with HD.

Huntington's Disease

Supernus Pharmaceuticals, Inc.189 participantsStarted Jan 2022

Little Rock, Arkansas, United States • La Jolla, California, United States • Los Angeles, California, United States +46 more locations

Find Trials by Condition in Nashville

Breast Cancerin Nashville Lung Cancerin Nashville Prostate Cancerin Nashville Colorectal Cancerin Nashville Melanomain Nashville Leukemiain Nashville Lymphomain Nashville Pancreatic Cancerin Nashville Ovarian Cancerin Nashville Brain Cancerin Nashville

Data from ClinicalTrials.govTerms

RECRUITING< 1 mile

Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

NCT01734122

The purpose of this study is to determine the changes in quality of life and degree of tremor for patients with essential tremor or Parkinsonian tremor who are treated by stereotactic radiosurgery (SRS). This is a questionnaire-based study. Please see Detailed Description below for more information.

TremorEssential TremorParkinson Disease+2 more

Vanderbilt University Medical Center60 participantsStarted Feb 2013

Nashville, Tennessee, United States

Active Not RecruitingNA< 1 mile

Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma.

NCT05024695

Evaluate the safety and effectiveness of iSTAR Medical's MINIject™ implant for lowering intraocular pressure (IOP) in subjects with primary open-angle glaucoma.

iSTAR Medical975 participantsStarted Aug 2021

Glendale, Arizona, United States • Fayetteville, Arkansas, United States • Beverly Hills, California, United States +34 more locations

COMPLETEDNA< 1 mile

Co-Use of Opioid Medications and Alcohol Prevention Study

NCT05599672

Previous research, including that of this team, shows that a significant portion of those regularly using opioids-particularly filling opioids at community pharmacies-also are involved in the co-use of alcohol. This study proposes to adapt a previously developed intervention for opioid medication misuse; test its acceptability, feasibility, and preliminary efficacy; and identify barriers and facilitators to large-scale research and system-level implementation. Results of this study will directly inform a fully-powered subsequent multisite trial.

Alcohol DrinkingOpioid Use

University of Utah112 participantsStarted May 2023

Nashville, Tennessee, United States

COMPLETEDPhase 3128 miles

Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children

NCT05634811

This study is to understand if the study vaccine (called VLA15) is safe in healthy children. We are looking for children who: * are healthy * are age 5 through 17 * have not been diagnosed with any form of Lyme disease in the past * have not received any vaccines for Lyme disease in the past Lyme disease happens most often in children of this age. The study vaccine may be used potentially to help prevent Lyme disease. The goal of this study is to get more information about the safety of the study vaccine in this age group. Participants will be in this study for about 2 years. During that time, they will receive VLA15 or placebo (sterile saltwater solution) by a "shot" in the arm. We will compare experience of children receiving VLA15 to those receiving the placebo. Participants will not know whether they get VLA15 or placebo. Everyone participating in this study will: * get the shots in a clinic or in a hospital office * receive a total of 4 shots * receive the first 3 shots within 6 months * receive the last shot about 1 year afterwards * need to come to the trial site for 6 planned visits; 4 of these are vaccination visits and 2 are follow-up visits. We will contact you by phone 1 time every year during the study to monitor your experience. You may have extra visits if you experience a severe reaction after a vaccine dose.

Pfizer3,549 participantsStarted Dec 2022

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Guntersville, Alabama, United States +62 more locations

COMPLETEDPhase 1160 miles

A Study in Adults to Investigate the Impact of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Venglustat Compared to Participants With Normal Hepatic Function

NCT05718258

This is a parallel, Phase 1, four arm, open-label, single dose, multicenter study to evaluate the impact of hepatic impairment on venglustat exposure following treatment with venglustat. The purpose of this study is to assess the effect of mild, moderate, and severe hepatic impairment on PK, safety, and tolerability of venglustat compared with normal hepatic function in male and female participants aged 18 to 79 years. Study details include: * The total study duration per participant will be up to 42 days, including up to 21 days for screening and approximately 21 days from institutionalization to the end of study (EOS). * Institutionalization is mandatory until the activities on D5 have been completed. * Each participant will receive a single dose of venglustat. * For hepatically impaired participants there will be a screening visit, a multi-day institutionalization visit, and 7 site visits after D5 discharge, including the end of study (EOS) visit. * For healthy volunteers there will be a screening visit, a multi-day institutionalization visit and 3 site visits after D5 discharge, including the end of study (EOS) visit.

Hepatic Function Abnormal

Sanofi26 participantsStarted Jan 2023

Rialto, California, United States • Miami, Florida, United States • Saint Paul, Minnesota, United States +3 more locations

Active Not RecruitingPhase 1/2179 miles

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

NCT01012817

This phase I/II trial studies the side effects and best dose of veliparib and topotecan hydrochloride and to see how well they work in treating patients with solid tumors, ovarian cancer that has come back or does not respond to treatment, or primary peritoneal cancer. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as topotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib with chemotherapy may kill more tumor cells.

Metastatic Malignant Solid NeoplasmRecurrent Fallopian Tube CarcinomaRecurrent Ovarian Carcinoma+2 more

National Cancer Institute (NCI)88 participantsStarted Nov 2009

Phoenix, Arizona, United States • Scottsdale, Arizona, United States • Sacramento, California, United States +12 more locations

Active Not RecruitingPhase 3179 miles

Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria

NCT05270837

This is a Phase 3 open-label randomized controlled study enrolling approximately 54 adolescents with PKU. The study is designed to assess the safety and efficacy of pegvaliase injections.

Phenylketonuria (PKU)

BioMarin Pharmaceutical55 participantsStarted Jun 2022

Phoenix, Arizona, United States • Little Rock, Arkansas, United States • Aurora, Colorado, United States +13 more locations

Active Not RecruitingPhase 3183 miles

Management of the PDA Trial

NCT03456336

Estimate the risks and benefits of active treatment versus expectant management of a symptomatic patent ductus arteriosus (sPDA) in premature infants.

Infant, PrematurePatent Ductus ArteriosusInfant, Newborn, Diseases+1 more

NICHD Neonatal Research Network836 participantsStarted Feb 2019

Birmingham, Alabama, United States • Palo Alto, California, United States • San Diego, California, United States +16 more locations

COMPLETEDNA183 miles

Tailored vs. Anatomical Ablation Strategy for Persistent Atrial Fibrillation

NCT04702451

Atrial Fibrillation (AF) ablation is typically performed in predefined anatomic regions of the left atrium without attempting to identify patient-specific areas of interest. This procedure is referred to as Pulmonary Vein Isolation (PVI). The hypothesis in this Study is that a tailored ablation strategy targeting areas of spatio-temporal dispersion in combination with PVI is superior to an anatomical ablation strategy targeting PVI alone for the treatment of persistent AF.

Atrial Fibrillation

Volta Medical377 participantsStarted Feb 2021

Birmingham, Alabama, United States • Jacksonville, Florida, United States • St Louis, Missouri, United States +23 more locations

COMPLETEDPhase 1215 miles

NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

NCT03107988

Lorlatinib is a novel inhibitor across ALK variants, including those resistant to crizotinib. In this first pediatric phase 1 trial of lorlatinib, the drug will be utilized as a single agent and in combination with chemotherapy in patients with relapsed/refractory neuroblastoma. The dose escalation phase of this study (Cohort A1) uses a traditional Phase I 3+3 design. Once a recommended phase 2 pediatric dose is identified, an expansion cohort of 6 patients (Cohort B1), within which ALKi naïve patients will be prioritized, will be initiated. Parallel cohorts will be initiated in adults or patients with large BSA (Cohort A2) and in combination with chemotherapy upon establishing RP2D (Cohort B2).

New Approaches to Neuroblastoma Therapy Consortium65 participantsStarted Sep 2017

Los Angeles, California, United States • San Francisco, California, United States • Aurora, Colorado, United States +10 more locations

COMPLETEDPhase 3253 miles

A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

NCT02752035

This was a clinical study for adult participants who were recently diagnosed with acute myeloid leukemia or AML. AML is a type of cancer. It is when bone marrow makes white blood cells that are not normal. These are called leukemia cells. Some participants with AML have a mutation, or change, in the FLT3 gene. This gene helps leukemia cells make a protein called FLT3. This protein causes the leukemia cells to grow faster. For participants with AML who could not receive standard chemotherapy, azacitidine (also known as Vidaza®) was a current standard of care treatment option in the United States. This clinical study tested an experimental medicine called ASP2215, also known as gilteritinib. Gilteritinib worked by stopping the leukemia cells from making the FLT3 protein. This helped stop the leukemia cells from growing faster. This study compared two different treatments. Participants were assigned to one of these two groups by chance: a medicine called azacitidine, also known as Vidaza®, or an experimental medicine gilteritinib in combination with azacitidine. There was a twice as much chance to receive both medicines combined than azacitidine alone. The clinical study may help show which treatment helps patients live longer.

Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

Astellas Pharma Global Development, Inc.183 participantsStarted Aug 2016

Los Angeles, California, United States • Orange, California, United States • Chicago, Illinois, United States +108 more locations

RECRUITINGNA253 miles

Clinical Utility of Residual Hearing in the Cochlear Implant Ear

NCT04707885

The current study is a randomized multi-center clinical trial that investigates the role an intraoperative hearing monitoring system (electrocochleography) has on helping to save residual hearing in patients undergoing cochlear implantation (CI).

Hearing Loss, SensorineuralHearing LossHearing Loss, Bilateral

Ohio State University40 participantsStarted Nov 2021

Rochester, Minnesota, United States • St Louis, Missouri, United States • Chapel Hill, North Carolina, United States +2 more locations

COMPLETEDPhase 1/2333 miles

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

NCT03878199

This phase I/II trial studies the best dose of ruxolitinib when given together with CPX-351 and to see how well they work in treating patients with accelerated phase or blast phase myeloproliferative neoplasm. Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. CPX-351 is a mixture of 2 chemotherapy drugs (daunorubicin and cytarabine) given for leukemia in small fat-based particles (liposomes) to improve the drug getting into cancer cells. Giving ruxolitinib and CPX-351 may work better in treating patients with secondary acute myeloid leukemia compared to CPX-351 alone.

Essential ThrombocythemiaMyelofibrosisMyeloproliferative Neoplasm+2 more

Ohio State University Comprehensive Cancer Center12 participantsStarted Feb 2019

Columbus, Ohio, United States • Portland, Oregon, United States • Dallas, Texas, United States

TERMINATEDPhase 1/2339 miles

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

NCT04278144

A first-in-human study using BDC-1001 as a single agent and in combination with nivolumab in HER2 expressing advanced malignancies

HER2-positive Solid TumorsHER2-positive Breast CancerHER2-positive Colorectal Cancer+2 more

Bolt Biotherapeutics, Inc.175 participantsStarted Feb 2020

Palo Alto, California, United States • Washington D.C., District of Columbia, United States • Chicago, Illinois, United States +18 more locations

COMPLETEDPhase 1432 miles

First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

NCT04000282

Primary Objectives: * Dose Escalation Part A: To determine the maximum tolerated dose (MTD) of SAR442085 administered as a single agent in patients with relapsed or refractory multiple myeloma (RRMM), and determine the recommended Phase 2 dose (RP2D) for the subsequent Expansion Part B * Dose Expansion Part B: To assess the antitumor activity of single agent of SAR442085 at the RP2D in patients with RRMM Secondary Objectives: * To characterize the safety profile of SAR442085 * To characterize the pharmacokinetics (PK) profile of SAR442085 when administered as a single agent * To evaluate the potential immunogenicity of SAR442085 * To assess preliminary evidence of antitumor activity in the Dose Escalation Part A

Plasma Cell Myeloma

Sanofi37 participantsStarted Aug 2019

Duarte, California, United States • Boston, Massachusetts, United States • Rochester, Minnesota, United States +9 more locations

COMPLETEDNA440 miles

PROmotion of COVID-19 BOOSTer VA(X)Ccination in the Emergency Department - PROBOOSTVAXED

NCT06156215

The goal of this cluster randomized clinical trial is to test the efficacy of messaging interventions to increase booster vaccine uptake in adults in the emergency department(ED). The main question\[s\] and goals of this study are: * does the intervention of vaccine messaging increase booster vaccine uptake at 30 days post ED visit? * does the intervention of asking about vaccine acceptance increase booster vaccine uptake at 30 days post ED visit? * considering recent national changes to funding and availability of updated vaccines, the investigators will examine the effects of these changes on vaccine acceptance and uptake in ED populations. Specifically, they will stratify EDs and ED patients according to the ED availability of vaccines, and they will also examine whether costs and availability of vaccines are a deterrent to patient acceptance and uptake of vaccines

University of California, San Francisco919 participantsStarted Jan 2024

San Francisco, California, United States • San Francisco, California, United States • Durham, North Carolina, United States +4 more locations

COMPLETEDPhase 1/2472 miles

A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)

NCT05459129

This is a Phase Ib/II, open-label, multicenter, randomized, umbrella study in participants with locally advanced squamous cell carcinoma of the head and neck (SCCHN). The study will enroll treatment-naive participants with resectable Stage III-IVA human papillomavirus (HPV)-negative, programmed death-ligand 1 (PD-L1)-positive SCCHN with measurable disease, as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) who have not received systemic treatment for their disease.

Squamous Cell Carcinoma of the Head and Neck

Hoffmann-La Roche12 participantsStarted Apr 2023

Duarte, California, United States • Philadelphia, Pennsylvania, United States • Pittsburgh, Pennsylvania, United States +3 more locations

SUSPENDEDPhase 1/21371 miles

Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells In Chronic Lung Disorders

NCT02946658

Chronic Obstructive Pulmonary Disease (COPD) is a lung-related disorder that is characterized by long-term, often progressive state of poor airflow. Primary symptoms include low oxygen tension, shortness of breath, productive cough, and broncho-pulmonary inflammation and interference with oxygen-carbon dioxide exchange. Air pollution and tobacco smoking are felt to be the most common cause of these issues. Diagnostic testing is based on poor airflow measured by lung function studies and whose symptoms do not improve much with antiasthma bronchodilators. Study is an interventional study to document the safety and efficacy of use of AD-cSVF in chronic broncho-pulmonary disease groups.

Healeon Medical Inc100 participantsStarted Oct 2016

Stevensville, Montana, United States • Roatán, HN, Honduras

PreviousPage 160 of 769Next

Diabetes

in Nashville

Heart Diseasein Nashville